Escient Pharmaceuticals, Inc.
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects with Atopic Dermatitis
Volunteers needed for up to a 14 week long clinical trial with up to 5 office visits for an investigational product. $1,250.00 stipend available. Additional compensation will be available for participants travelling further than 62.1 miles (100 Km).
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18+ years of age (max age = 80)
2.) Have MILD to MODERATE eczema (atopic dermatitis)
3.) Minimum of 3% eczema affected body surface area (max 20%) to be determined by Investigator at Screening Visit.
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Allergic to lidocaine
2.) Unwilling to discontinue current atopic dermatitis treatments
3.) Female who is pregnant or breastfeeding
ClinicalTrials.gov Identifier: NCT https://clinicaltrials.gov/study/NCT06144424?cond=Atopic%20Dermatitis&term=escient&rank=1
Escient Pharmaceuticals, Inc Logo
We love our patients, so feel free to visit during normal business hours.
510 S Cowley Spokane, WA 99202
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.